SCHEMBL2510033

SCHEMBL2510033

CCCN1Cc2cc(OCc3cnccc3-c3ccccc3)ccc2C1=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.43
PRMT5 O14744 2/20 0.42
WDR77 Q9BQA1 2/20 0.42
GRM1 Q13255 2/20 0.41
GRM5 P41594 2/20 0.41
CD274 Q9NZQ7 1/20 0.41
ADAM17 P78536 3/20 0.40
F10 P00742 1/20 0.40
ITGB3 P05106 2/20 0.39
ITGA2B P08514 1/20 0.39
ITGAV P06756 1/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2509656 0.87 PRMT5 (0.41) EGFRPRMT5WDR77GRM1GRM5
SCHEMBL2512868 0.86 PRMT5 (0.42) EGFRPRMT5WDR77CD274ADAM17
SCHEMBL2512685 0.84 ADAM17 (0.40) EGFRPRMT5WDR77GRM1GRM5
SCHEMBL3638895 0.81 ADAM17 (0.42) EGFRPRMT5WDR77GRM1GRM5
SCHEMBL2507478 0.79 ITGB3 (0.44) EGFRGRM1GRM5ADAM17F10
SCHEMBL2512573 0.79 ADAM17 (0.39) EGFRPRMT5WDR77GRM5ADAM17
SCHEMBL2510944 0.77 IDH1 (0.42) EGFRGRM1GRM5F10ITGB3
SCHEMBL2511076 0.77 PRMT5 (0.37) PRMT5WDR77GRM1GRM5ADAM17
SCHEMBL2514240 0.76 IDH1 (0.40) GRM1GRM5
SCHEMBL3640741 0.76 ADAM17 (0.41) EGFRGRM1GRM5ADAM17F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664214-B2 Small molecule potentiators of metabotropic glutamate receptors I AbbVie Deutschland GmbH & Co. KG (DE) 2014-03-04 US claimed
US-8664214-B2 Small molecule potentiators of metabotropic glutamate receptors I AbbVie Deutschland GmbH & Co. KG (DE) 2014-03-04 US disclosed
US-20110245232-A1 NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I ABBOTT GMBH & CO. KG (DE) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245232-A1 NOVEL SMALL MOLECULE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS I GRM3, GRIN2C, GRIN2B EGFR 1711/4885PRMT5 1226/4885WDR77 2121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.